Carcinogenesis, Vol. 20, No. 4, 591-597,
April 1999
© 1999 Oxford University Press
Role of p53 gene mutations in human esophageal carcinogenesis: results from immunohistochemical and mutation analyses of carcinomas and nearby non-cancerous lesions
Laboratory for Cancer Research, College of Pharmacy, Rutgers University, Piscataway, NJ 08855–0789, USA and
1 Henan Medical University, Zhengzhou, Henan, China
In order to characterize p53 alterations in esophageal cancer and to study their roles in carcinogenesis, we performed gene mutation and immunohistochemical analysis on 43 surgically resected human esophageal specimens, which contain squamous cell carcinoma (SCC) and adjacent non-cancerous lesions, from a high-incidence area of Linzhou in Henan, China. A newly developed immunohisto-selective sequencing (IHSS) method was used to enrich the p53 immunostain-positive cells for mutation analysis. p53 gene mutations were detected in 30 out of 43 (70%) SCC cases. Among 29 SCC cases that were stained positive for p53 protein, 25 (86%) were found to contain p53 mutations. In five cases of SCC with homogeneous p53 staining, the same mutation was observed in samples taken from four different positions of each tumor. In a well differentiated cancer nest, p53 mutation was detected in only the peripheral p53-positive cells. In tumor areas with heterogeneous p53 staining, either the area stained positive for p53 had an additional mutation to the negatively stained area or both areas lacked any detectable p53 mutation. In the p53-positive non-cancerous lesions adjacent to cancer, p53 mutations were detected in seven out of 16 (47%) samples with basal cell hyperplasia (BCH), eight out of 12 (67%) samples with dysplasia (DYS), and six out of seven (86%) samples with carcinoma in situ (CIS). All mutations found in lesions with DYS and CIS were the same as those in the nearby SCC. In seven cases of BCH containing mutations, only three had the same mutations as the nearby SCC. The results suggest that p53 mutation is an early event in esophageal carcinogenesis occurring in most of the DYS and CIS lesions, and cells with such mutations will progress to carcinoma, whereas the role of p53 mutations in BCH is less clear.
Abbreviations: BCH, basal cell hyperplasia; CIS, carcinoma in situ; DYS, dysplasia; IHSS, immunohisto-selective sequencing; SCC, squamous cell carcinoma; SSCP, single strand conformation polymorphism; wt, wild-type.
2 To whom correspondence should be addressed Email: csyang{at}rci.rutgers.edu
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. Zhang, L. Xu, D. Xiao, J. Xie, H. Zeng, Z. Wang, X. Zhang, Y. Niu, Z. Shen, J. Shen, et al. Upregulation of neutrophil gelatinase-associated lipocalin in oesophageal squamous cell carcinoma: significant correlation with cell differentiation and tumour invasion J. Clin. Pathol., May 1, 2007; 60(5): 555 - 561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H Zhang, L Xu, D Xiao, J Xie, H Zeng, W Cai, Y Niu, Z Yang, Z Shen, and E Li Fascin is a potential biomarker for early-stage oesophageal squamous cell carcinoma J. Clin. Pathol., September 1, 2006; 59(9): 958 - 964. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Z. Fang, C. Liu, Y. Song, G.-Y. Yang, Y. Nie, J. Liao, X. Zhao, Y. Shimada, L.-D. Wang, and C. S. Yang Over-expression of gastrin-releasing peptide in human esophageal squamous cell carcinomas Carcinogenesis, June 1, 2004; 25(6): 865 - 871. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-K. So, Y. Nie, Y. Song, G.-Y. Yang, S. Chen, C. Wei, L.-D. Wang, N. A. Doggett, and C. S. Yang Loss of Heterozygosity and Internal Tandem Duplication Mutations of the CBP Gene Are Frequent Events in Human Esophageal Squamous Cell Carcinoma Clin. Cancer Res., January 1, 2004; 10(1): 19 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Shirai, T. Tsukamoto, M. Yamamoto, T. Iidaka, H. Sakai, T. Yanai, T. Masegi, L. A. Donehower, and M. Tatematsu Elevated susceptibility of the p53 knockout mouse esophagus to methyl-N-amylnitrosamine carcinogenesis Carcinogenesis, September 1, 2002; 23(9): 1541 - 1547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Smeds, P. Berggren, X. Ma, Z. Xu, K. Hemminki, and R. Kumar Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16INK4a and p14ARF ) and p53 genes are major targets for inactivation Carcinogenesis, April 1, 2002; 23(4): 645 - 655. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Hu, J. Huang, M. R. Emmert-Buck, Z.-Z. Tang, M. J. Roth, C. Wang, S. M. Dawsey, G. Li, W.-J. Li, Q.-H. Wang, et al. Frequent Inactivation of the TP53 Gene in Esophageal Squamous Cell Carcinoma from a High-Risk Population in China Clin. Cancer Res., April 1, 2001; 7(4): 883 - 891. [Abstract] [Full Text]
|
|
|
|
|
|
K.-W. Chang, S. Sarraj, S.-C. Lin, P.-I Tsai, and D. Solt p53 expression, p53 and Ha-ras mutation and telomerase activation during nitrosamine-mediated hamster pouch carcinogenesis Carcinogenesis, July 1, 2000; 21(7): 1441 - 1451. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Robert, P. Michel, J. M. Flaman, A. Chiron, C. Martin, F. Charbonnier, B. Paillot, and T. Frebourg High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis Carcinogenesis, April 1, 2000; 21(4): 563 - 565. [Abstract] [Full Text] [PDF]
|
|